Inactive Instrument

Roche Holding Ltd. Stock London S.E.

Equities

CH0012032048

Pharmaceuticals

Sales 2024 * 60.61B 68.07B Sales 2025 * 63.99B 71.87B Capitalization 200B 225B
Net income 2024 * 13.25B 14.89B Net income 2025 * 14.74B 16.56B EV / Sales 2024 * 3.54 x
Net Debt 2024 * 14.08B 15.82B Net Debt 2025 * 9B 10.11B EV / Sales 2025 * 3.27 x
P/E ratio 2024 *
14.6 x
P/E ratio 2025 *
13.2 x
Employees -
Yield 2024 *
3.95%
Yield 2025 *
4.06%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding Ltd.

Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 66 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company